Becton Dickinson (NYSE:BDX) Stock

Becton Dickinson

Becton, Dickinson

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.

Becton, Dickinson and Company Common Stock

Becton Dickinson & Co

Becton Dickinson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) short percent of float has risen 32.32% since its last report. The company recently reported that it has 3.79 million shares sold short, which is 1.31% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.85 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Becton Dickinson Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744826426_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Becton Dickinson has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Becton Dickinson's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Becton Dickinson's peer group average for short interest as a percentage of float is 4.48%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Is Becton Dickinson Gaining or Losing Market Support?

Integration of BD Phoenix&#x2122; Automated Microbiology System, BDXpert&#x2122; System and BD Synapsys&#x2122; Informatics Solution Supports Accurate Detection of Antimicrobial Resistance
FRANKLIN LAKES, N.J. (April 9, 2025) – BD (Becton, Dickinson and Company) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for BD Phoenix&#x2122; M50 and BDXpert&#x2122; System on the BD Synapsys&#x2122; Informatics Solution, leveraging rapid identification (ID) and antimicrobial susceptibility testing (AST) algorithms to assist in the interpretation of complex diagnostic data to help ensure accurate and reliable diagnoses related to antimicrobial resistance (AMR).

Biotech

News

General

BD Receives FDA 510(k) Clearance For Advanced Microbiology Solution

BD Announces First Patient Treated In Investigational Device Exemption Trial Intended To Achieve FDA Premarket Approval For Use Of GalaFLEX LITE Scaffold In Breast Implant Revision Surgery

Becton Dickinson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) short percent of float has fallen 21.09% since its last report. The company recently reported that it has 2.94 million shares sold short, which is 1.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.8 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Becton Dickinson Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742229027_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Becton Dickinson has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Becton Dickinson's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Becton Dickinson's peer group average for short interest as a percentage of float is 4.24%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Do Investors Really Feel About Becton Dickinson?

Barclays analyst Travis Steed maintains Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) with a Overweight and raises the price target from $278 to $279.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Becton Dickinson, Raises Price Target to $279

On Wednesday, Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) authorized to pursue a plan to separate BD&#8217;s Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus, and growth-oriented investments <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43511126/bd-announces-intent-to-separate-biosciences-and-diagnostic-solutions-business-to-enhance-focus-dri" rel="noreferrer noopener">and capital allocation</a>.
Following the separation, New BD will be a pure-play medical technology company. It expects to drive concentrated investments in high-impact R&amp;D and disciplined capital allocation, including growth-accretive M&amp;A.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43443889/starboard-value-pushes-becton-dickinson-to-divest-life-sciences-unit" rel="noreferrer noopener">Activist Starboard Value Pushes Becton Dickinson To Divest Life Sciences Unit</a>
Medical Essentials includes BD&#8217;s Medication Delivery Solutions and Specimen Management businesses, which manufacture products such as IV catheters, PICCS, flush and other essential vascular access and management solutions, blood collection solutions, syringes, and advanced needle technologies.
Connected Care includes BD&#8217;s Medication Management Solutions and Advanced Patient Monitoring businesses with smart devices that use automation, artificial intelligence, and analytics.
BioPharma Systems provides biologic drug delivery, development, and manufacturing of drug delivery devices for the pharmaceutical industry.
Interventional, which includes BD&#8217;s Urology &amp; Critical Care, Peripheral Intervention, and Surgery businesses, caters to conditions such as urinary incontinence, peripheral vascular disease, cancer, and hernias.
After the separation, the New BD is expected to have fiscal 2024 revenue of approximately&nbsp;$17.8 billion. Biosciences and Diagnostic Solutions is expected to have approximately&nbsp;$3.4 billion&nbsp;in fiscal 2024 revenue.
The company expects to announce more specifics on the separation plans by the end of fiscal 2025 and intends to target completion of the transaction in fiscal 2026.
In April 2022, Becton Dickinson spun off&nbsp;Embecta Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NYSE">EMBC</a>), a diabetes device maker, <a target="_blank" href="https://www.benzinga.com/25/02/43443889/starboard-value-pushes-becton-dickinson-to-divest-life-sciences-unit" rel="noreferrer noopener">into a standalone entity</a>.
In November, the company announced that it had decided to discontinue its insulin patch pump program and would&nbsp;<a target="_blank" href="https://www.benzinga.com/24/11/42197315/becton-dickinson-spinoff-embecta-stops-insulin-patch-pump-program-plans-restructuring-stock-jumps" rel="noreferrer noopener">initiate a restructuring plan</a>.
In July, Embecta, a manufacturer of disposable&nbsp;insulin pen needles&nbsp;and syringes, said it is considering a potential sale following a significant drop in its share price since being spun off from health tech&nbsp;<a target="_blank" href="https://www.benzinga.com/m-a/24/07/39916116/insulin-device-maker-embecta-weighs-sale-after-70-share-decline-following-becton-dickinson-spin-off" rel="noreferrer noopener">giant&nbsp;Becton, Dickinson</a>.
Concurrently, BD reported first-quarter 2025 adjusted EPS of $3.43 beating the consensus of $2.98. The company&#8217;s sales increased 9.8% year-over-year to $5.17 billion, beating the <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus of $5.1 billion</a>.
Guidance: BD updated its fiscal year 2025 revenue guidance from $21.9 billion-$22.1 billion to $21.7 billion-$21.9 billion compared to the consensus of $21.93 billion.
The company expects adjusted EPS of $14.30-$14.60, up from $14.25-$14.60 compared to the consensus of $14.40.
Price Action: BDX stock is down 3.88% at $235.56 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43527607/conocophillips-beats-q4-revenue-and-eps-estimates-sets-10b-return-of-capital-target" target="_blank" rel="noreferrer noopener">ConocoPhillips Beats Q4 Revenue And EPS Estimates, Sets $10B Return of Capital Target</a></li>
</ul>

Earnings

Guidance

Health Care

Movers

EMBC

Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business

WIIM

Becton, Dickinson and Company shares are trading lower following Q1 financial results.

BD On Updates FY25 Revenue Guidance From $21.9B-$22.1B To $21.7B-$21.9B vs $21.933B Est.; Updated FY25 Adj. EPS Guidance From $14.25-$14.60 To $14.30-$14.60 vs $14.40 Est.

Earnings Beats

Becton, Dickinson Q1 2025 Adj. EPS $3.43 Beats $2.98 Estimate, Sales $5.168B Beat $5.100B Estimate

Becton, Dickinson And Company Plans To Separate Biosciences And Diagnostic Solutions Business From The Rest Of BD

Activist investor Starboard Value has taken a stake in Becton, Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) and is pressing the $72 billion medical technology company to sell its <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41419988/tylenol-listerine-maker-kenvue-under-activist-spotlight-with-starboard-value-stake-overhaul-ahea" rel="noreferrer noopener">life sciences division</a>.
The hedge fund has met with Becton Dickinson's management and sent a letter to the board urging the divestiture of the unit, which supplies products for clinical and research laboratories. The size of Starboard's stake remains undisclosed.
Other shareholders have also begun advocating for the separation of the life sciences division, aligning with recent analyst reports suggesting that a spin-off could unlock significant value.
The Financial Times report <a target="_blank" href="https://www.ft.com/content/69c614b4-1b52-43f0-ba8a-a3d8283cb576" rel="noreferrer noopener">writes</a> that in December, Bank of America analysts noted that the disparity between Becton Dickinson's current valuation and its potential "sum of the parts" was becoming too substantial to ignore. They estimated that a split could boost the company's value by up to 30%.
In April 2022, Becton Dickinson spun off Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>), a diabetes device maker, into a standalone entity.
In November, the company announced that it had decided to discontinue its insulin patch pump program and would <a target="_blank" href="https://www.benzinga.com/24/11/42197315/becton-dickinson-spinoff-embecta-stops-insulin-patch-pump-program-plans-restructuring-stock-jumps" rel="noreferrer noopener">initiate a restructuring plan</a>.
In July, Embecta, a manufacturer of disposable&nbsp;insulin pen needles&nbsp;and syringes, said it is considering a potential sale following a significant drop in its share price since being spun off from health tech&nbsp;<a target="_blank" href="https://www.benzinga.com/m-a/24/07/39916116/insulin-device-maker-embecta-weighs-sale-after-70-share-decline-following-becton-dickinson-spin-off" rel="noreferrer noopener">giant&nbsp;Becton, Dickinson</a>.
In December, The Securities and Exchange Commission announced it had&nbsp;settled charges&nbsp;against Becton, Dickinson for repeatedly misleading investors about risks associated with its continued sales of its Alaris infusion pump and for overstating its income by failing to record the costs of fixing multiple software <a target="_blank" href="https://www.benzinga.com/news/legal/24/12/42635199/financial-crime-weekly-becton-dickinson-and-co-pays-175-million-penalty-express-fails-to-disclose-ceos-full-compensation" rel="noreferrer noopener">flaws with the pump</a>. The company agreed to pay a $175 million civil penalty.
Last week, Starboard Value <a target="_blank" href="https://www.benzinga.com/25/01/43244840/whats-going-on-with-pfizer-stock-monday" rel="noreferrer noopener">decided not to pursue</a> a&nbsp;proxy battle with Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>).
Starboard announced that it built a&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41199793/amid-pfizers-struggles-with-declining-demand-for-covid-19-treatments-activist-investor-starboard" rel="noreferrer noopener">$1 billion stake in the pharmaceutical giant</a> in October. The activist investor was reportedly planning to push for changes at the company given the stock's recent underperformance.
Price Action: BDX stock is up 1.03% at $250.16 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/02/43439786/beyond-snaps-up-buy-buy-baby-brand-for-5-million-details" target="_blank" rel="noreferrer noopener">Beyond Snaps Up Buy Buy Baby Brand For $5 Million: Details</a></li>
</ul>

Large Cap

Hedge Funds

Media

Activist Starboard Value Pushes Becton Dickinson To Divest Life Sciences Unit

Becton Dickinson shares are trading higher after the Financial Times reported Starboard Value has taken a stake in the company and is pushing for a sale of its life sciences division.

Asset Sales

UPDATE: Financial Times Reported Starboard Value Has Taken A Stake In Becton Dickinson And Is Pushing The  Company To Sell Its Life Sciences Division

<a href="https://www.ft.com/content/69c614b4-1b52-43f0-ba8a-a3d8283cb576" title="https://www.ft.com/content/69c614b4-1b52-43f0-ba8a-a3d8283cb576">https://www.ft.com/content/69c614b4-1b52-43f0-ba8a-a3d8283cb576</a>

Contracts

Financial Times Reported Starboard Pushes Becton Dickinson To Spin Off Unit

Buybacks

BD Board Authorized 10M Additional Share Repurchase

Piper Sandler analyst Jason Bednar maintains Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) with a Overweight and raises the price target from $275 to $280.

Piper Sandler Maintains Overweight on Becton Dickinson, Raises Price Target to $280

The S&amp;P 500 is charging into the final week of January at record highs, breaking above 6,100 points as investors digest a cocktail of economic optimism, earnings strength, and major <a href="https://www.benzinga.com/topic/donald-trump">policy shifts from Washington.</a>
At the center of this market euphoria is Donald Trump. The <a href="https://www.benzinga.com/government/regulations/25/01/43085323/trump-sworn-in-as-47th-president-declares-golden-age-of-america-begins-right-now">newly sworn-in</a> 47th U.S. president began his first week with a series of executive orders targeting <a href="https://www.benzinga.com/government/regulations/25/01/43086509/trump-unleashes-executive-orders-on-border-security-oil-drilling-domestic-manufacturing-in-first-acts-as-president">trade, immigration and oil</a>. Some orders have immediate effects, others are symbolic, and several <a href="https://www.npr.org/2025/01/21/g-s1-44023/trump-birthright-citizenship-immigration-order-14th-amendment">face</a> legal challenges.
On Tuesday, Trump also <a href="https://www.benzinga.com/etfs/sector-etfs/25/01/43135764/trumps-500-billion-stargate-ai-plan-puts-3-etfs-in-focus">unveiled plans for AI Stargate</a>, a $500 billion project. And on Thursday, Trump appeared in a <a href="https://www.youtube.com/watch?v=DKBWckduL2k">video address</a> at Davos, touting that the U.S. will be &#8220;the world capital of artificial intelligence and crypto.&#8221;
Meanwhile, there's a quieter trend playing out: The final week of January has historically been a positive period for stocks, and data suggests a handful of S&amp;P 500 names could be primed for outsized gains.
<h3 class="wp-block-heading">January's Final Week Sparked By Optimism </h3>
Seasonality isn't always a reliable predictor in markets, but when patterns persist for nearly a century, they demand attention. 
Data from Seasonax reveals that January has closed in positive territory 60% of the time over the past 97 years, with an average gain of 1.1%.
What's even more striking is that more than half of those gains have occurred in the final week of the month.
Since 1928, the S&amp;P 500 has climbed 0.6% on average in the last week of January, closing higher 61% of the time. 
<h3 class="wp-block-heading">5 Stocks With a History Of Late-January Gains</h3>
Historical patterns don't dictate the future, but they often coincide. 
And according to two decades of market data, five S&amp;P 500 stocks have consistently outperformed during the final stretch of January.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Stock</th>
<th>Avg. Return (Final Jan. Week)</th>
<th>Positive Closes (Last 20 Yrs)</th>
<th>Best Performance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hologic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>)</td>
<td>4.08% (Jan. 23 &#8211; Feb. 2)</td>
<td>14 out of 20 years</td>
<td>36.58% in 2005</td>
</tr>
<tr>
<td>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>2.7% (Jan. 23 &#8211; Jan. 30)</td>
<td>16 out of 20 years</td>
<td>16.2% in 2009</td>
</tr>
<tr>
<td>NRG Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>)</td>
<td>2.5% (Jan. 23 &#8211; Feb. 2)</td>
<td>14 out of 20 years</td>
<td>21.04% in 2016</td>
</tr>
<tr>
<td>Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>)</td>
<td>1.9% (Jan. 23 &#8211; Jan. 31)</td>
<td>13 out of 20 years</td>
<td>21% in 2009</td>
</tr>
<tr>
<td>Becton, Dickinson &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>)</td>
<td>1.56% (Jan. 23 &#8211; Feb. 2)</td>
<td>14 out of 20 years</td>
<td>9.8% in 2005</td>
</tr>
</tbody>
</table>
</figure>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43169109/blackrocks-larry-fink-warns-that-new-inflationary-pressures-could-shock-the-stock-market-it-could-be-pretty-bad">BlackRock&#8217;s Larry Fink Warns That New Inflationary Pressures Could &#8216;Shock&#8217; The Stock Market: &#8216;It Could Be Pretty Bad&#8217;</a></li>
</ul>
Image: Shutterstock

AMZN

HOLX

ORCL

5 S&P 500 Stocks Set To Shine In The Final Week Of January — If History Repeats Itself

Together, the companies intend to develop new software capabilities within BD flow cytometer instrument software to be compatible with Biosero's Green Button Go software, as well as jointly support biopharmaceutical and contract research organizations with their custom research needs, to enable easy integration with robotic arms.

BD (Becton, Dickinson And Company) And Biosero Announced A Framework Collaboration Agreement To Enable And Facilitate Robotic Arm Integration With BD Flow Cytometry Instruments To Accelerate Drug Discovery And Development

Carilion Clinic In Partnership With Becton, Dickinson And Company Announced That Carilion Is The First Health System In The State And The Southeastern U.S. To Provide Its Patients Needle-free Blood Draws Using The BD PIVO Pro Needle-free Blood Collection Device

Press Releases

Carilion Clinic First in Virginia to Offer Needle-free In-patient Blood Draws, Redefining Patient Standard of Care

BD and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and Development

Dividends

BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $750 Million Repurchase to Date in FY25

BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value

BD Reports First Quarter Fiscal 2025 Financial Results

BD to Present at Investor Healthcare Conferences

BD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery

Comments

Becton Dickinson

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL